{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.4","upperLimit":"4.2","value":"4.0"},{"groupId":"OG001","lowerLimit":"2.1","upperLimit":"2.2","value":"2.1"},{"groupId":"OG002","lowerLimit":"3.7","upperLimit":"5.0","value":"4.2"},{"groupId":"OG003","lowerLimit":"2.1","upperLimit":"4.2","value":"2.4"},{"groupId":"OG004","lowerLimit":"3.6","upperLimit":"4.2","value":"4.1"},{"groupId":"OG005","lowerLimit":"2.1","upperLimit":"2.2","value":"2.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"464"},{"groupId":"OG001","value":"467"},{"groupId":"OG002","value":"118"},{"groupId":"OG003","value":"116"},{"groupId":"OG004","value":"309"},{"groupId":"OG005","value":"316"}],"units":"Participants"}],"description":"PFS was defined as the time between the date of randomization and the date of first documented progression of disease (PD) or death, whichever occurred first. PD was determined on the basis of investigator assessment with use of RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters had to demonstrate an absolute increase of \\>/= 5 millimeters (mm).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants randomized to the chemotherapy arm received vinflunine, paclitaxel, or docetaxel per the investigators choice. Vinflunine 320 milligrams per square meter (mg/m\\^2), paclitaxel 175 mg/m\\^2, or docetaxel 75 mg/m\\^2 were administered intravenously on Day 1 of each 21-day cycle until disease progression per standard RECIST v1.1 or unacceptable toxicity.","id":"OG000","title":"Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)"},{"description":"Atezolizumab was administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants received atezolizumab as long as they continued to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.","id":"OG001","title":"Atezolizumab"},{"description":"PD-L1 immunohistochemistry (IHC) score of IC2/3","id":"OG002","title":"IC2/3 Chemotherapy"},{"description":"PD-L1 immunohistochemistry (IHC) score of IC2/3","id":"OG003","title":"IC2/3 Atezolizumab"},{"description":"PD-L1 immunohistochemistry (IHC) score of IC1/2/3","id":"OG004","title":"IC1/2/3 Chemotherapy"},{"description":"PD-L1 immunohistochemistry (IHC) score of IC1/2/3","id":"OG005","title":"IC1/2/3 Atezolizumab"}],"paramType":"MEDIAN","populationDescription":"Intent To Treat (ITT) was defined as all randomized participants, irrespective of whether the assigned treatment was actually received.","reportingStatus":"POSTED","timeFrame":"Up to approximately 25 months after first participant enrolled","title":"Progression-free Survival (PFS) as Determined by the Investigator With Use of RECIST v1.1","type":"SECONDARY","unitOfMeasure":"months"}